Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson, Kristen B. McCullough, Betsy R. LaPlant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2024) 144 (23): 2456–2461.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Yael Kusne, Talha Badar, Terra L. Lasho, Ludovica Marando, Abhishek A. Mangaonkar, Christy Finke, James M. Foran, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Jeanne Palmer, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 440.

https://doi.org/10.1182/blood-2024-203879

Published: 2024

Journal Articles

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

Clifford M. Csizmar, Anuya A. Natu, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Sanam Loghavi, Alexandre Bazinet, Terra L. Lasho, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 6747.

https://doi.org/10.1182/blood-2024-209126

Published: 2024

Journal Articles

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Blood (2024) 144 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2024-193917

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, Aasiya Matin, William J. Hogan, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Mithun V Shah, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 6700.

https://doi.org/10.1182/blood-2024-201128

Published: 2024

Journal Articles

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Blood (2024) 144 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2024-202406

Published: 2024

Journal Articles

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Terra L. Lasho, Jenna A. Fernandez, Jeong-Heon Lee, Linh D. Pham, Huihuang Yan, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Naseema Gangat, Joseph Collard, Claes Wahlestedt, Mrinal M. Patnaik, Moritz Binder

Blood (2024) 144 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2024-204070

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Blood (2024) 144 (Supplement 1): 1820.

https://doi.org/10.1182/blood-2024-209193

Published: 2024

Journal Articles

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Ayalew Tefferi, Saubia Fathima, Ali Khalid Alsugair, Clifford M. Csizmar, Mark Gurney, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Hassan B Alkhateeb, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2024-207736

Published: 2024

Journal Articles

Clonal Hematopoiesis Landscape in Metastatic Prostate Cancer Patients

Yael Kusne, Osama Mosalem, Kevin Thompson, Krishna Kalari, Winston Tan, Leila A Jones, Brian A Costello, Daniel Childs, Abhishek A. Mangaonkar, Jenna A. Fernandez, Christy Finke, Terra L. Lasho, Richard Weinshilboum, Leiwei Wang, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 5644.

https://doi.org/10.1182/blood-2024-206483

Published: 2024

Journal Articles

A Prospective Cohort Study of Biologic and Chronologic Aging in 106 Patients with Age and Context-Relevant Clonal Hematopoiesis

Marissa Li, Jenna A. Fernandez, Kristina Kirschner, Tamir Chandra, Kristen B. McCullough, Sarah Aug, Terra L. Lasho, Christy Finke, Naseema Gangat, Abhishek A. Mangaonkar, Rachel A Simon, Alejandro Ferrer, Mrinal M. Patnaik, James M. Foran, Cecilia Y. Arana Yi, Yael Kusne, Talha Badar

Blood (2024) 144 (Supplement 1): 5632.

https://doi.org/10.1182/blood-2024-206069

Published: 2024

Journal Articles

Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Blood (2024) 144 (Supplement 1): 2134.1.

https://doi.org/10.1182/blood-2024-207952

Published: 2024

Journal Articles

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Mahmoud Yacout, Bahga Katamesh, Yazan Jabban, Rong He, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Abhishek A. Mangaonkar, Mithun V Shah, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2024-208957

Published: 2024

Journal Articles

Natural History and Predictors of Survival in Adult Patients with Telomere Biology Disorders

Enrica Quattrocchi, Eva M. Carmona Porquera, Alejandro Diaz Arumir Vergara, Ana C. Zamora, Laura Ongie, Kristen B. McCullough, Brittany Burnap, Jenna A. Fernandez, Doug A. Simonetto, Patrick S. Kamath, Avni Joshi, Mark E. Wylam, Cassie C. Kennedy, Terra L. Lasho, Christy Finke, Rachel A. Simon, Mrinal M. Patnaik, Alejandro Ferrer, Abhishek A. Mangaonkar

Blood (2024) 144 (Supplement 1): 1326.

https://doi.org/10.1182/blood-2024-210391

Published: 2024

Journal Articles

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2024-204114

Published: 2024

Journal Articles

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Nadia Toumeh, Yazan Jabban, Ahmad Nanaa, Rong He, David Viswanatha, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, William J. Hogan, Mithun V Shah, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2024-209413

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations

Blood (2024) 144 (Supplement 1): 3218.

https://doi.org/10.1182/blood-2024-202688

Published: 2024

Journal Articles

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2024-198269

Published: 2024

NARROW

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Clonal Hematopoiesis Landscape in Metastatic Prostate Cancer Patients

A Prospective Cohort Study of Biologic and Chronologic Aging in 106 Patients with Age and Context-Relevant Clonal Hematopoiesis

Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Natural History and Predictors of Survival in Adult Patients with Telomere Biology Disorders

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations

Evidence-Based Risk Stratification of TP53 -Mutated Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only